Evidence map›Paper›PMID 42726138›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer.

Daniel Li, Edward B Garon

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel LiUniversity of California, Los Angeles Los Angeles, CA United States.ORCID 0000-0003-4293-4509
Edward B GaronUniversity of California, Los Angeles Santa Monica, CA United States.ORCID 0000-0001-7077-8801

Funding

HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapyR01CA276917 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EDWARD B GARON · 2023 to 2026
$2.9M
NCI NIH HHS R01 CA276917
6 · The paper itself

Abstract

MTAP loss is among the most common potentially targetable driver mutations in NSCLC. Early phase clinical trials are ongoing. Although susceptible to various biases, retrospective studies may serve as a historical control to interpret single arm studies. Combination therapies and novel biomarkers may also improve objective response rates.

Identifiers

PMID42726138
PMCPMC13573827

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.